Biofrontera Wins Patent Case, Sun Pharma Patent Ruled Unpatentable
Biofrontera announced that on February 23, 2026, the U.S. Patent Trial and Appeal Board issued a Final Written Decision finding all challenged claims of Sun Pharmaceutical Industries, Inc.'s U.S. Patent No. 11,697,028 to be unpatentable. As previously disclosed in Biofrontera's filings with the Securities and Exchange Commission, in June 2024, Sun Pharma initiated proceedings against Biofrontera and certain of its affiliates in the U.S. District Court for the District of Massachusetts and the International Trade Commission alleging infringement of the '028 Patent and a related patent, U.S. Patent No. 11,446,512. In response to these proceedings, Biofrontera challenged the validity of Sun Pharma's asserted claims by filing petitions for Inter Partes Review with the Board. The Board has now agreed with Biofrontera on all challenged claims of the '028 Patent. Sun Pharma has the right to request a review of the decision or appeal it to the United States Court of Appeals for the Federal Circuit. The decision does not affect the petition filed by the Company relating to the '512 patent, which was denied review by the Patent Office on administrative, rather than substantive, grounds. "Biofrontera is pleased with the Board's Final Written Decision.," commented Hermann Luebbert, CEO and Chairman of Biofrontera. "We remain focused on clinical research and development in the PDT space to better serve clinicians and improve their patients' lives."
Trade with 70% Backtested Accuracy
Analyst Views on BFRI
About BFRI
About the author
Biofrontera to Report 2025 Financial Results on March 19
- Financial Reporting Schedule: Biofrontera will announce its financial results for the year ended December 31, 2025, after the U.S. market closes on March 19, 2026, reflecting the company's commitment to financial transparency.
- Conference Call Timing: The company will host a conference call at 10:00 AM ET on the same day to discuss the financial results and provide a business update, aiming to bolster investor confidence in the company's future prospects.
- Product Focus Area: Biofrontera specializes in photodynamic therapy (PDT), commercializing the drug-device combination Ameluz® with the RhodoLED® lamp series for treating precancerous skin lesions, showcasing its expertise in dermatological treatments.
- Clinical Trial Expansion: The company is conducting clinical trials to extend the use of its products to treat non-melanoma skin cancers and moderate-to-severe acne, indicating its proactive approach to product development and market expansion potential.
Biofrontera Announces Ameluz® Clinical Trial Results
- Clinical Trial Results: Biofrontera's Phase 2b study demonstrated that Ameluz® achieved a 57.97% reduction in inflammatory acne lesions with a 3-hour incubation, significantly outperforming the control group's 36.51%, indicating the treatment's potential in acne management.
- Efficacy Assessment: In the mIGA analysis, 25% of patients treated with Ameluz® met the co-primary endpoint compared to 21.4% in the vehicle group, further validating Ameluz®'s effectiveness in improving skin conditions.
- Safety and Tolerability: Ameluz® exhibited a favorable safety profile, with treatment-related adverse events primarily consisting of mild to moderate burning sensations and pruritus, and average pain scores during the 3-hour treatments ranged from 3.4 to 3.8, indicating good tolerability.
- Market Potential: Acne vulgaris is one of the most common dermatological conditions in the U.S., and Biofrontera plans to present these findings to the FDA in Q3 2026 to seek approval for Ameluz® in treating moderate to severe acne, thereby expanding its dermatology product line.
BIOFRONTERA INC PLANS TO SUBMIT PHASE 2B DATA FOR AMELUZ PDT TO FDA IN Q3 2026
Project Overview: The BioFrontier AI initiative is set to present Phase 2 data for the Ameluz PDT treatment in Q3 2026.
Focus on Ameluz: The data presentation will specifically highlight the efficacy and outcomes of Ameluz in photodynamic therapy (PDT).
BIOFRONTERA INC - AMELUZ PDT SHOWS POSITIVE SAFETY RESULTS IN PHASE 2B TRIAL
Study Overview: A Phase 2 study by BioFrontier AI demonstrates a favorable safety profile for a new treatment.
Implications for Treatment: The findings suggest potential advancements in therapeutic options based on the study's results.
BIOFRONTERA INC - PHASE 2B STUDY DEMONSTRATES SIGNIFICANTLY LOWER INFLAMMATORY ACNE LESIONS WITH AMELUZ PDT
Study Overview: A Phase 2 study has been conducted to evaluate the effects of a treatment on inflammatory acne lesions.
Results: The study shows a significant reduction in inflammatory acne lesions with the use of the treatment, Ameluz PDT.
BIOFRONTERA INC. ANNOUNCES ENCOURAGING PHASE 2B RESULTS FOR CONTINUED DEVELOPMENT OF AMELUZ® PHOTODYNAMIC THERAPY IN TREATING MODERATE TO SEVERE ACNE VULGARIS
Positive Phase 2 Results: BioFrontier AI has reported positive results from Phase 2 trials supporting the development of its AmeLuz® photodynamic therapy.
Targeted Condition: The therapy is aimed at treating moderate to severe acne vulgaris, indicating a potential advancement in acne treatment options.
Biofrontera to Report 2025 Financial Results on March 19
- Financial Reporting Schedule: Biofrontera will announce its financial results for the year ended December 31, 2025, after the U.S. market closes on March 19, 2026, reflecting the company's commitment to financial transparency.
- Conference Call Timing: The company will host a conference call at 10:00 AM ET on the same day to discuss the financial results and provide a business update, aiming to bolster investor confidence in the company's future prospects.
- Product Focus Area: Biofrontera specializes in photodynamic therapy (PDT), commercializing the drug-device combination Ameluz® with the RhodoLED® lamp series for treating precancerous skin lesions, showcasing its expertise in dermatological treatments.
- Clinical Trial Expansion: The company is conducting clinical trials to extend the use of its products to treat non-melanoma skin cancers and moderate-to-severe acne, indicating its proactive approach to product development and market expansion potential.
Biofrontera Announces Ameluz® Clinical Trial Results
- Clinical Trial Results: Biofrontera's Phase 2b study demonstrated that Ameluz® achieved a 57.97% reduction in inflammatory acne lesions with a 3-hour incubation, significantly outperforming the control group's 36.51%, indicating the treatment's potential in acne management.
- Efficacy Assessment: In the mIGA analysis, 25% of patients treated with Ameluz® met the co-primary endpoint compared to 21.4% in the vehicle group, further validating Ameluz®'s effectiveness in improving skin conditions.
- Safety and Tolerability: Ameluz® exhibited a favorable safety profile, with treatment-related adverse events primarily consisting of mild to moderate burning sensations and pruritus, and average pain scores during the 3-hour treatments ranged from 3.4 to 3.8, indicating good tolerability.
- Market Potential: Acne vulgaris is one of the most common dermatological conditions in the U.S., and Biofrontera plans to present these findings to the FDA in Q3 2026 to seek approval for Ameluz® in treating moderate to severe acne, thereby expanding its dermatology product line.
BIOFRONTERA INC PLANS TO SUBMIT PHASE 2B DATA FOR AMELUZ PDT TO FDA IN Q3 2026
Project Overview: The BioFrontier AI initiative is set to present Phase 2 data for the Ameluz PDT treatment in Q3 2026.
Focus on Ameluz: The data presentation will specifically highlight the efficacy and outcomes of Ameluz in photodynamic therapy (PDT).
BIOFRONTERA INC - AMELUZ PDT SHOWS POSITIVE SAFETY RESULTS IN PHASE 2B TRIAL
Study Overview: A Phase 2 study by BioFrontier AI demonstrates a favorable safety profile for a new treatment.
Implications for Treatment: The findings suggest potential advancements in therapeutic options based on the study's results.
BIOFRONTERA INC - PHASE 2B STUDY DEMONSTRATES SIGNIFICANTLY LOWER INFLAMMATORY ACNE LESIONS WITH AMELUZ PDT
Study Overview: A Phase 2 study has been conducted to evaluate the effects of a treatment on inflammatory acne lesions.
Results: The study shows a significant reduction in inflammatory acne lesions with the use of the treatment, Ameluz PDT.
BIOFRONTERA INC. ANNOUNCES ENCOURAGING PHASE 2B RESULTS FOR CONTINUED DEVELOPMENT OF AMELUZ® PHOTODYNAMIC THERAPY IN TREATING MODERATE TO SEVERE ACNE VULGARIS
Positive Phase 2 Results: BioFrontier AI has reported positive results from Phase 2 trials supporting the development of its AmeLuz® photodynamic therapy.
Targeted Condition: The therapy is aimed at treating moderate to severe acne vulgaris, indicating a potential advancement in acne treatment options.
